Neuropathic pain syndrome is a challenge to treat and ... Moreover, interindividual variability in drug response, and genetic polymorphism in particular, is an emerging aspect to consider.

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Direct comparative studies are needed of the safety and efficacy of drugs used to treat neuropathic pain.

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain. According to GlobalData, Phase I drugs for Peripheral Neuropathic Pain have an 89% ...

The following is a summary of “A Double-Blind Comparative Study of burstDR Versus Tonic Epidural Motor Cortex Stimulation for ...

The University of Cincinnati’s Jun-Ming Zhang has received a five-year, $3.1 million grant from the National Institute of ...

A top NYC weight-loss doctor shared the surprising skin complication that he’s encountered in patients using GLP-1 drugs like ...

In this edition of “Rising High,” The Fly conducted an exclusive interview with Erez Aminov, Chairman & Chief Executive Officer of MIRA ...